The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain will allow mixing of COVID-19 vaccines on rare occasions

Sat, 02nd Jan 2021 13:02

By Andrew MacAskill

LONDON, Jan 2 (Reuters) - Britain will allow people to be
given shots of different COVID-19 vaccines on rare occasions,
despite a lack of evidence about the extent of immunity offered
by mixing doses.

In a departure from other strategies globally, the
government said people could be given a mix-and-match of two
COVID-19 shots, for example if the same vaccine dose was out of
stock, according to guidelines published on New Year's Eve.

"(If) the same vaccine is not available, or if the first
product received is unknown, it is reasonable to offer one dose
of the locally available product to complete the schedule,"
according to the guidelines.

Mary Ramsay, head of immunisations at Public Health England,
said this would only happen on extremely rare occasions, and
that the government was not recommending the mixing of vaccines,
which require at least two doses given several weeks apart.

"Every effort should be made to give them the same vaccine,
but where this is not possible it is better to give a second
dose of another vaccine than not at all," she said.

COVID-19 has killed more 74,000 people in Britain - the
second-highest death toll in Europe, and health officials are
racing to deliver doses to help end the pandemic as fears grow
that the health service could be overwhelmed.

Earlier this week, the government reactivated emergency
hospitals built at the start of the outbreak as wards fill up
with COVID-19 patients.

Britain has been at the forefront of approving the new
coronavirus vaccines, becoming the first country to give
emergency authorisation to the Pfizer/BioNTech and the
AstraZeneca/University of Oxford vaccines last month.

Both vaccines are meant to be administered as two shots,
given several weeks apart, but they were not designed to be
mixed together.

The government's new guidelines said there "is no evidence
on the interchangeability of the COVID-19 vaccines although
studies are underway".

However, the advice said that while every effort should be
made to complete the dosing regimen with the same vaccine, if
the patient is at "immediate high risk" or is considered
"unlikely to attend again" they can be given different vaccines.

Britain sparked controversy earlier this week by announcing
plans to delay giving the coronavirus vaccine booster shot in an
attempt to ensure more people could be given the more limited
protection conferred by a single dose.

The top U.S. infectious diseases expert, Anthony Fauci, said
on Friday he did not agree with the British approach of delaying
the second dose up to 12 weeks.

"I would not be in favour of that," he told CNN. "We're
going to keep doing what we're doing."
(Reporting by Andrew MacAskill
Editing by Helen Popper)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.